The global biopharmaceutical third party logistics (3PL) market size reached US$ 123.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 195.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 123.0 Billion |
Market Forecast in 2032
|
US$ 195.4 Billion |
Market Growth Rate 2024-2032 | 5.2% |
Biopharmaceutical third-party logistics (3PL) refer to the services outsourced by pharmaceutical companies through third-party organizations. It involves receiving small molecule drugs, vaccines, biologics and other medical products into the warehouse, fulfilling orders and handling inventory of the goods through a warehouse management system. 3PL assists pharma and medical institutions in maintaining the logistics for delivering medical therapies, reducing medicine prices by minimizing wasteful overhead expenses, ensuring uninterrupted product supply, improving transportation services and enhancing the overall efficiencies of the organization.
Significant growth in the pharmaceutical industries is one of the key factors creating a positive outlook for the market. Furthermore, the emerging trend of outsourcing logistics by various medical organizations to optimize their distribution network is providing a thrust to the market growth. As the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for 3PL logistics to minimize drug supply disruptions and prioritize the availability of critical care drugs. Various technological advancements, such as the launch of warehouse robotics, mobile cloud computing, real-time monitoring and data mining solutions, are acting as other growth-inducing factors. These technologies aid in automating logistics-related processes and minimizing operation complexities, human errors and damages caused to the products in transit. In line with this, near field communication (NFC) and internet of thing (IoT)-based cold chain monitoring products are also being used to manage temperature-sensitive pharmaceutical products and get real-time updates and alerts regarding the shipments.
IMARC Group provides an analysis of the key trends in each sub-segment of the global biopharmaceutical third party logistics (3PL) market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on supply chain and service type.
Breakup by Supply Chain:
Breakup by Service Type:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agility Logistics, AmerisourceBergen Corporation, DB Schenker (Deutsche Bahn), DHL International GmbH (Deutsche Post), FedEx Corporation, Kerry Logistics Network Limited, Kuehne + Nagel International AG, McKesson Corporation, SF Express Co. Ltd. and United Parcel Service of America Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2023 |
Historical Period | 2018-2023 |
Forecast Period | 2024-2032 |
Units | US$ Billion |
Segment Coverage | Supply Chain, Service Type, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Agility Logistics, AmerisourceBergen Corporation, DB Schenker (Deutsche Bahn), DHL International GmbH (Deutsche Post), FedEx Corporation, Kerry Logistics Network Limited, Kuehne + Nagel International AG, McKesson Corporation, SF Express Co. Ltd. and United Parcel Service of America Inc. |
Customization Scope | 10% Free Customization |
Report Price and Purchase Option | Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899 |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
According to the estimates by IMARC Group, the global biopharmaceutical third party logistics (3PL) market is expected to grow at a CAGR of 5.2% during 2024-2032.
The increasing adoption of outsourced logistics services by various medical organizations to optimize their distribution network represents one of the key drivers for the global biopharmaceutical third party logistics (3PL) market.
The rising integration of 3PL services with warehouse robotics, mobile cloud computing, real-time monitoring, and data mining solutions, represents one of the key trends in the global biopharmaceutical third party logistics (3PL) market.
Sudden outbreak of the COVID-19 pandemic had led to a significant increase in the demand for 3PL logistics to minimize drug supply disruptions and prioritize the availability of critical care drugs.
On the basis of the supply chain, the market has been divided into cold chain and non-cold chain. Among these, non-cold chain represents the largest segment.
On the basis of the service type, the market has been bifurcated into transportation, warehousing and storage, and others. Currently, warehousing and storage holds the majority of the total market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global biopharmaceutical third party logistics (3PL) market are Agility Logistics, AmerisourceBergen Corporation, DB Schenker (Deutsche Bahn), DHL International GmbH (Deutsche Post), FedEx Corporation, Kerry Logistics Network Limited, Kuehne + Nagel International AG, McKesson Corporation, SF Express Co. Ltd., and United Parcel Service of America Inc.